HC Wainwright Has Bearish Forecast for RVMD Q1 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Investment analysts at HC Wainwright dropped their Q1 2025 EPS estimates for Revolution Medicines in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($1.09) for the quarter, down from their previous estimate of ($0.92). HC Wainwright currently has a "Buy" rating and a $73.00 target price on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for Revolution Medicines' Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.17) EPS and FY2025 earnings at ($4.51) EPS.

A number of other equities analysts also recently commented on the company. Guggenheim boosted their price objective on Revolution Medicines from $82.00 to $87.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. Needham & Company LLC lowered their price target on shares of Revolution Medicines from $60.00 to $59.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Stifel Nicolaus reduced their price objective on shares of Revolution Medicines from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Wedbush reaffirmed an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a research report on Thursday, February 27th. Finally, UBS Group increased their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Twelve analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $66.31.

Remove Ads

Revolution Medicines Stock Down 6.1 %

NASDAQ RVMD traded down $2.39 during trading hours on Thursday, hitting $36.82. 1,818,704 shares of the company were exchanged, compared to its average volume of 1,363,635. The firm has a market cap of $6.85 billion, a price-to-earnings ratio of -10.26 and a beta of 1.46. The company has a 50 day moving average of $41.59 and a two-hundred day moving average of $46.05. Revolution Medicines has a 52-week low of $29.55 and a 52-week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11).

Insider Activity

In other news, COO Margaret A. Horn sold 4,329 shares of Revolution Medicines stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $196,536.60. Following the completion of the sale, the chief operating officer now directly owns 127,991 shares in the company, valued at $5,810,791.40. The trade was a 3.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jack Anders sold 2,635 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $119,629.00. Following the transaction, the chief financial officer now directly owns 96,470 shares in the company, valued at $4,379,738. The trade was a 2.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,678 shares of company stock worth $847,981 over the last three months. 8.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Revolution Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Boxer Capital Management LLC acquired a new stake in shares of Revolution Medicines during the fourth quarter worth $187,184,000. Janus Henderson Group PLC increased its stake in shares of Revolution Medicines by 54.5% during the 4th quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after acquiring an additional 3,346,755 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Revolution Medicines by 14.7% during the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after acquiring an additional 2,185,082 shares during the period. Farallon Capital Management LLC boosted its position in shares of Revolution Medicines by 17.1% in the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock worth $579,498,000 after acquiring an additional 1,931,000 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Revolution Medicines in the third quarter worth approximately $83,082,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.